Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 Plus Gefitinib Versus Gefitinib Monotherapy for First-line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With EGFR-sensitive Mutation
NCT03457337Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Mar 2018
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tegafur in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Progression Free Survival at 2 years. Status: unknown.
02
Drugs
tegafur
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03457337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03457337.